Pfizer's Challenge On Generic Marketing Exclusivity Waivers Rejected By FDA

Waiver and relinquishment of generic marketing exclusivity are permitted under the FD&C Act and promote marketplace competition, FDA says. Pfizer asserted that treating 180-day exclusivity as an "alienable" asset would encourage the filing of speculative ANDAs.